glp 1 compound ending 🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these Compounded GLP-1s: Why doctors worry

Accessed 1/27/2015

According to SURPASS-2 clinical trials, it has shown to be very effective in treating type 2 diabetes, especially compared to other drugs on the market, such as semaglutide

We start with comprehensive lab work that goes beyond a basic metabolic panel

Contact your healthcare provider if you experience: Absent periods (amenorrhea): Missing three or more consecutive menstrual cycles if previously regular, or six or more months if previously irregular Heavy bleeding (menorrhagia): Soaking through a pad or tampon every hour for several consecutive hours, or periods lasting longer than seven days Severe pain: New or worsening menstrual cramping not relieved by over-the-counter medications Intermenstrual bleeding: Bleeding or spotting between periods that persists beyond initial treatment months Pregnancy possibility: Any missed period when pregnancy is possible, as tirzepatide is not recommended during pregnancy Urgent warning signs: Heavy bleeding with dizziness, fainting, rapid heartbeat, or severe weakness requires emergency evaluation Your healthcare provider may recommend specific investigations to evaluate persistent menstrual irregularities